Vivax Malaria Clinical Trial
— GAPOfficial title:
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
Verified date | October 2020 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a single-arm observational cohort study. Malaria patients with Plasmodium vivax
and meeting study inclusion criteria, who give consent to be enrolled in the study, will have
their G6PD status measured by the CareStartâ„¢ G6DP rapid diagnostic test (G6PD RDT), and
primaquine prescribed according to the result. According to the G6PD RDT result, primaquine
will be prescribed at 0.25mg/kg/day for 14 days (normal patients) or 0.75mg/kg weekly for
eight weeks (deficient patients). All will receive treatment with chloroquine to clear
asexual stages of infection.
Patients will be reviewed at day 2, day 7 and day 14. At these visits patients will undergo a
brief clinical assessment and a small blood sample will be taken for repeat haemoglobin
measurement and dried blood spot for carboxyprimaquine measurement (day 7 and day 14 only).
In general, antimalarial treatment will be unsupervised to reflect field conditions. However
a subset of 25 G6PD normal patients at a single site will have each day of their primaquine
treatment administered and observed at the treatment centre. This is to determine a
calibration curve for primaquine pharmacokinetic studies.
Dried blood spots will be stored appropriately. Day zero samples will be genotyped in Bangkok
(MORU, Dr. Mallika Imwong) after DNA extraction. PCR-RFLP will be used to detect the allele
associated with the Mediterranean variant of G6PD deficiency. In addition DNA extracts will
be sent for more systematic genetic testing for known G6PD variants through existing
collaborations with the Wellcome Trust Sanger Institute. The day 7 and 14 dried blood spot
samples will be analysed in the MORU pharmacology laboratory for primaquine and
carboxyprimaquine concentrations, from which adherence to primaquine can be determined
retrospectively, using the subset of 25 patients receiving directly observed therapy to
calibrate the results.
Funder: WellcomeTrust, Grant reference: 107548/Z/15/Z
Status | Completed |
Enrollment | 1000 |
Est. completion date | November 2018 |
Est. primary completion date | November 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months and older |
Eligibility |
Inclusion Criteria: - Adults and children >6 months - Confirmed diagnosis of Plasmodium vivax mono-infection - Ability to swallow oral medication - Participant (or parent/guardian if <15 years old) is willing and able to give documented informed consent and comply with study requirements Exclusion Criteria: - Severe malaria (see World Health Organisation definition) - P. falciparum infection - Pregnancy or lactation - Hypersensitivity (allergy) to primaquine or chloroquine - Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study e.g. other acute febrile conditions or chronic disease - Ongoing involvement in another research study |
Country | Name | City | State |
---|---|---|---|
Afghanistan | Dr. Ghulam Rahim Awab MD | Jalalabad | Nangarha |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | Mahidol Oxford Tropical Medicine Research Unit, Nangarhar University |
Afghanistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of CareStartâ„¢ G6PD rapid test compared to a genotyping result as gold-standard | 3 years | ||
Primary | Specificity of CareStartâ„¢ G6PD rapid test compared to a genotyping result as gold-standard | 3 years | ||
Secondary | Percentage of P. vivax patients receiving a correct primaquine prescription after G6PD testing compared to using phenotype as gold standard | 3 years | ||
Secondary | Level of primaquine metabolite in dried blood spots collected after treatment | Day 2, 7, 14 | 2, 7 and 14 days | |
Secondary | Level of whole blood carboxyprimaquine at day 7 | 7 days | ||
Secondary | Level of whole blood carboxyprimaquine at day 14 | 14 days | ||
Secondary | The degree to which healthcare workers act appropriately on the results of G6PD testing in terms of primaquine prescription | 3 years | ||
Secondary | Barriers to long-term use of the approach based on a qualitative questionnaire-based survey | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01625871 -
Artemether/Lumefantrine and Vivax Malaria
|
Phase 3 | |
Completed |
NCT01218932 -
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04228315 -
Biomarkers of P. Vivax Relapse
|
N/A | |
Completed |
NCT02118090 -
Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:
|
Phase 4 | |
Completed |
NCT01074905 -
Study on the Treatment of Vivax Malaria
|
Phase 3 | |
Completed |
NCT04222088 -
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
|
||
Completed |
NCT01546961 -
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
|
N/A | |
Completed |
NCT00158548 -
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
|
Phase 3 | |
Completed |
NCT00682578 -
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
|
Phase 3 | |
Completed |
NCT00157833 -
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
|
N/A | |
Active, not recruiting |
NCT03529396 -
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
|
Phase 2 | |
Recruiting |
NCT05874271 -
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
|
N/A | |
Completed |
NCT05958797 -
TES of Chloroquine for Pv in the Philippines in 2016
|
||
Completed |
NCT01716260 -
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
|
N/A | |
Completed |
NCT01288820 -
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
|
Phase 3 | |
Completed |
NCT01640574 -
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
|
Phase 3 | |
Completed |
NCT01076868 -
Incidence of Vivax Along the Thai Burma Border
|
N/A | |
Completed |
NCT00158561 -
Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria
|
Phase 3 | |
Completed |
NCT01780753 -
Primaquine Pharmacokinetics in Lactating Women and Their Infants
|
Phase 1 | |
Completed |
NCT06044805 -
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
|
Phase 4 |